14963 completed, 4970 unknown, 4869 recruiting, 4711 terminated. 35507 Phase 2, 7295 Phase 1, 1261 Phase 3.
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Withdrawn | Actuate Therapeutics Inc. | 2030-12-18 | 2022-02-22 | |
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp | Phase 2 | Not yet recruiting | Vejle Hospital | 110 | 2028-02-01 | 2026-04-30 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor Pimicotinib, Tumor resection surgery - Tenosynovial Giant Cell Tumor, Diffuse | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 84 | 2027-10-01 | 2026-07-16 |
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients Aminolevulinic acid hydrochloride - Pediatric Brain Tumor | Phase 2 | Not yet recruiting | Costas Hadjipanayis | 20 | 2027-08-01 | 2026-10-07 |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Rintatolimod - Pancreatic Cancer | Phase 2 | Suspended | AIM ImmunoTech Inc. | 90 | 2027-08-01 | 2026-08-19 |
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Combination Immunotherapy Targeting Sarcomas Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-07-01 | 2026-11-02 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
Showing 20 of 35507. Sign in to see all of them.
Breast Neoplasms (3588) · Carcinoma, Non-Small-Cell Lung (3130) · Prostatic Neoplasms (1924) · Colorectal Neoplasms (1870) · Multiple Myeloma (1583) · Leukemia, Myeloid, Acute (1553) · Neoplasm Metastasis (1454) · Lung Neoplasms (1421) · Melanoma (1334) · Lymphoma (1276) · Pancreatic Neoplasms (1253) · Ovarian Neoplasms (1181) · Recurrence (1143) · Carcinoma, Hepatocellular (1110)
Neoplasms by Site (23909) · Neoplasms by Histologic Type (17918) · Hemic and Lymphatic Diseases (8245) · Neoplasms, Glandular and Epithelial (7511) · Digestive System Diseases (7137) · Digestive System Neoplasms (6977) · Immune System Diseases (6308) · Immunoproliferative Disorders (6073) · Lymphoproliferative Disorders (6011) · Urogenital Diseases (5737) · Hematologic Diseases (5499) · Skin and Connective Tissue Diseases (5485) · Carcinoma (5475) · Skin Diseases (5447)
Cyclophosphamide (1776) · Cisplatin (1761) · Carboplatin (1651) · Gemcitabine (1464) · Paclitaxel (1417) · Radiotherapy (1385) · Bevacizumab (1362) · pembrolizumab (1356) · Docetaxel (1199) · Oxaliplatin (1018) · Capecitabine (1001) · Fluorouracil (955) · Rituximab (926) · Dexamethasone (911) · Nivolumab (886)
National Cancer Institute (NCI) (1669) · M.D. Anderson Cancer Center (1156) · Memorial Sloan Kettering Cancer Center (677) · Sun Yat-sen University (506) · Fudan University (452) · Dana-Farber Cancer Institute (342) · Novartis Pharmaceuticals (295) · Eli Lilly and Company (277) · Hoffmann-La Roche (250) · Mayo Clinic (242) · Alliance for Clinical Trials in Oncology (236) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (236) · Pfizer (208) · AstraZeneca (203) · Fred Hutchinson Cancer Center (202)
United States (17835) · China (6250) · France (2765) · Canada (2323) · Spain (2261) · Italy (2172) · Germany (2112) · United Kingdom (1924) · South Korea (1672) · Australia (1335) · Belgium (1224) · Netherlands (1104) · Taiwan (804) · Japan (802) · Poland (802)
Stanislaw R. Burzynski, MD, PhD (55)
PMID 37185961, PMID 31401903, PMID 41671463, PMID 34515338, PMID 32499241, PMID 35622074, PMID 37146227, PMID 36648215, PMID 19097774, PMID 30207593, PMID 40812353, PMID 38979716, PMID 25057165, PMID 35623069, PMID 34037241, PMID 40135712, PMID 40550489, PMID 32632956, PMID 33538338, PMID 39863139, PMID 25667295, PMID 27238653, PMID 33337539, PMID 33357481, PMID 34398557, PMID 35170751, PMID 37934000, PMID 39319495, PMID 22473314, PMID 23524640, PMID 26884585, PMID 28410911, PMID 31395089, PMID 34393061, PMID 35101941, PMID 37407274, PMID 39462179, PMID 40340830, PMID 15496622, PMID 20375404, PMID 22555974, PMID 23065508, PMID 23633099, PMID 25577718, PMID 26291023, PMID 26808342, PMID 27209293, PMID 28054442, PMID 28712102, PMID 28835440
2023 (321), 2017 (213), 2016 (205), 2025 (186), 2018 (185), U10CA032102 (173), 2019 (167), 2014 (166), 2009 (160), 2015 (157), P30CA015083 (137), P30CA033572 (133), 2008 (126), P30CA015704 (125), U10CA031946 (122)